Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.
Seong CS, Huang C, Boese AC, Hou Y, Koo J, Mouw JK, Rupji M, Joseph G, Johnston HR, Claussen H, Switchenko JM, Behera M, Churchman M, Kolesar JM, Arnold SM, Kerrigan K, Akerley W, Colman H, Johns MA, Arciero C, Zhou W, Marcus AI, Ramalingam SS, Fu H, Gilbert-Ross M. Seong CS, et al. Among authors: fu h. bioRxiv [Preprint]. 2023 Jan 27:2023.01.26.525772. doi: 10.1101/2023.01.26.525772. bioRxiv. 2023. PMID: 36747658 Free PMC article. Preprint.
Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer.
Koo J, Seong CS, Parker RE, Dwivedi B, Arthur RA, Dinasarapu AR, Johnston HR, Claussen H, Tucker-Burden C, Ramalingam SS, Fu H, Zhou W, Marcus AI, Gilbert-Ross M. Koo J, et al. Among authors: fu h. bioRxiv [Preprint]. 2023 Jun 14:2023.06.14.544941. doi: 10.1101/2023.06.14.544941. bioRxiv. 2023. Update in: Cancer Res. 2024 Nov 15;84(22):3761-3771. doi: 10.1158/0008-5472.CAN-23-2631 PMID: 37398244 Free PMC article. Updated. Preprint.
Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease.
Du Y, Bradshaw WJ, Leisner TM, Annor-Gyamfi JK, Qian K, Bashore FM, Sikdar A, Nwogbo FO, Ivanov AA, Frye SV, Gileadi O, Brennan PE, Levey AI; Emory-Sage-SGC TREAT-AD Center; Axtman AD, Pearce KH, Fu H, Katis VL. Du Y, et al. Among authors: fu h. bioRxiv [Preprint]. 2023 May 22:2023.05.22.541727. doi: 10.1101/2023.05.22.541727. bioRxiv. 2023. Update in: J Biol Chem. 2023 Dec;299(12):105382. doi: 10.1016/j.jbc.2023.105382 PMID: 37292860 Free PMC article. Updated. Preprint.
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM.
Bashore FM, Katis VL, Du Y, Sikdar A, Wang D, Bradshaw WJ, Rygiel KA, Leisner TM, Chalk R, Mishra S, Williams AC, Gileadi O, Brennan PE, Wiley JC, Gockley J, Cary GA, Carter GW, Young JE, Pearce KH, Fu H; Emory-Sage-SGC TREAT-AD Center; Axtman AD. Bashore FM, et al. Among authors: fu h. bioRxiv [Preprint]. 2023 Jul 29:2023.07.28.551026. doi: 10.1101/2023.07.28.551026. bioRxiv. 2023. Update in: PLoS One. 2024 Feb 15;19(2):e0293548. doi: 10.1371/journal.pone.0293548 PMID: 37547005 Free PMC article. Updated. Preprint.
[No title available]
[No authors listed] [No authors listed] PMID: 39751171
Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM, Chimenti ML, Zhang DY, Williams EK, Moore SG, Humber GM, Baxter TA, Birnbaum LA, Qui M, Zecca H, Thapa A, Jain J, Jui NT, Wang X, Fu H, Du Y, Kemp ML, Lam WA, Graham DK, DeRyckere D, Dreaden EC. Kelvin JM, et al. Among authors: fu h. J Control Release. 2023 Sep;361:470-482. doi: 10.1016/j.jconrel.2023.07.045. Epub 2023 Aug 14. J Control Release. 2023. PMID: 37543290 Free PMC article.
8,432 results